GBI Research has released its latest research, “Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity” which provides insights into the licensing agreements of large pharmaceutical companies. The report provides an in-depth analysis of the major licensing agreement trends in the pharmaceutical industry along with product and technology licensing trends. In addition, the report also analyzes the top 20 pharmaceutical companies with respect to the licensing agreement activities. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

Scope

• The scope of this report includes:
• Major market trends that are expected to shape the licensing and deal making landscape in pharmaceutical industry
• Trends in deals for product licensing and technology licensing agreements.
• Extensive research and analysis of the licensing activity of large pharmaceutical companies.
• Licensing and deal making segmentation of top 20 in the pharmaceutical companies by phase, type, geography and value
• Company profiles of leading biotech companies active in licensing and deal making

Reasons to Buy

• The report will enhance your decision making capability. It will allow you to
• Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the pharmaceutical industry.
• Enable better product lifecycle management by identifying key phases of product licensing agreements.
• Develop segment specific strategies for licensing and deal making in pharmaceutical industry.
• Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading pharma companies.
• Accelerate and strengthen your market position by identifying key companies for licensing agreements.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Licensing Strategies In Large Pharmaceutical Companies – Introduction
2.1 Licensing Agreement – An Authorization
2.2 GBI Research Report Guidance
3 Trends in In-licensing and Out-licensing Agreements
3.1 In-Licensing Compensates For Declining Internal R&D
3.2 Licensing Key To Combat Patent Cliff
3.3 Spiraling Cost of Licensing Deals
3.3.1 Competition to Restock Pipelines
3.3.2 Biotechs Push Products through Further Stages of Development
4 Product Licensing
4.1 Licensing Offsets Deficiencies in Internal Pipelines and Portfolios
4.2 Oncology Therapy Area Spearheads Licensing Agreements in Big Pharma Companies
4.3 Licensing Deals in Asia-Pacific on the Rise
5 Technology Licensing Deals
5.1 Importance of Technology In-Licensing
5.2 Technology Licensing With Universities
6 Major Licensing Deals of Big Pharma Companies – 2010
6.1 High Value Deals of Big Pharma Players – 2010
6.1.1 GlaxoSmithKline Enters Into Licensing Agreement with Isis Pharmaceuticals
6.1.2 Sanofi-Aventis enters Into Licensing Agreement with Avila Therapeutics
6.1.3 Boehringer Ingelheim Enters into Licensing Agreement With f-star Biotechnologische
6.1.4 Merck Amends Its Collaboration Agreement with Ariad Pharmaceuticals
6.1.5 AstraZeneca Enters Into Licensing Agreement with Rigel Pharmaceuticals
7 Licensing Strategies of Major Pharma Companies
7.1 GlaxoSmithKline
7.1.1 Overview
7.1.2 Licensing Agreements – GSK
7.1.3 By Value
7.1.4 By Type
7.1.5 By Geography
7.1.6 By Therapy Area
7.1.7 By Phase
7.2 J&J
7.2.1 Overview
7.2.2 Licensing Agreements – J&J
7.2.3 By Value
7.2.4 By Type
7.2.5 By Geography
7.2.6 By Therapy Area
7.2.7 By Phase
7.3 Roche
7.3.1 Overview
7.3.2 Licensing Agreements – Roche
7.3.3 By Value
7.3.4 By Type
7.3.5 By Geography
7.3.6 By Therapy Area
7.3.7 By Phase
7.4 Abbott
7.4.1 Overview
7.4.2 Licensing Agreements – Abbott
7.4.3 By Value
7.4.4 By Type
7.4.5 By Geography
7.4.6 By Therapy Area
7.4.7 By Phase
7.5 Eli Lilly
7.5.1 Overview
7.5.2 Licensing Agreements – Eli Lilly
7.5.3 By Value
7.5.4 By Type
7.5.5 By Geography
7.5.6 By Therapy Area
7.5.7 By Phase
7.6 Novartis
7.6.1 Overview
7.6.2 Licensing Agreements – Novartis
7.6.3 By Value
7.6.4 By Type
7.6.5 By Geography
7.6.6 By Therapy Area
7.6.7 By Phase
7.7 Sanofi
7.7.1 Overview
7.7.2 Licensing Agreements – Sanofi
7.7.3 By Value
7.7.4 By Type
7.7.5 By Geography
7.7.6 By Therapy Area
7.7.7 By Phase
7.8 Takeda
7.8.1 Overview
7.8.2 Licensing Agreements – Takeda
7.8.3 By Value
7.8.4 By Type
7.8.5 By Geography
7.8.6 By Therapy Area
7.8.7 By Phase
7.9 Pfizer
7.9.1 Overview
7.9.2 Licensing Agreements – Pfizer
7.9.3 By Value
7.9.4 By Type
7.9.5 By Geography
7.9.6 By Therapy Area
7.9.7 By Phase
7.10 Bristol-Myers Squibb
7.10.1 Overview
7.10.2 Licensing Agreements – Bristol-Myers Squibb
7.10.3 By Value
7.10.4 By Type
7.10.5 By Geography
7.10.6 By Therapy Area
7.10.7 By Phase
7.11 Boehringer-Ingelheim
7.11.1 Overview
7.11.2 Licensing Agreements – Boehringer Ingelheim
7.11.3 By Value
7.12 Merck & Co.
7.12.1 Overview
7.12.2 Licensing Agreements – Merck & Co.
7.12.3 By Value
7.12.4 By Type
7.12.5 By Geography
7.12.6 By Therapy Area
7.12.7 By Phase
7.13 Bayer
7.13.1 Overview
7.13.2 Licensing Agreements – Bayer
7.13.3 By Value
7.13.4 By Type
7.13.5 By Geography
7.13.6 By Therapy Area
7.13.7 By Phase
7.14 AstraZeneca
7.14.1 Overview
7.14.2 Licensing Agreements – AstraZeneca
7.14.3 By Value
7.14.4 By Type
7.14.5 By Geography
7.14.6 By Therapy Area
7.14.7 By Phase
7.15 Astellas
7.15.1 Overview
7.15.2 Licensing Agreements – Astellas
7.15.3 By Value
7.15.4 By Type
7.15.5 By Geography
7.15.6 By Therapy Area
7.15.7 By Phase
7.16 Daiichi-Sankyo
7.16.1 Overview
7.16.2 Licensing Agreements – Daiichi Sankyo
7.16.3 By Value
7.16.4 By Type
7.16.5 By Geography
7.16.6 By Therapy Area
7.16.7 By Phase
7.17 Teva Pharma
7.17.1 Overview
7.17.2 Licensing Agreements – Teva
7.17.3 By Value
7.17.4 By Geography
7.17.5 By Therapy Area
7.17.6 By Phase
7.18 Eisai
7.18.1 Overview
7.18.2 Licensing Agreements – Eisai
7.18.3 By Value
7.18.4 By Type
7.18.5 By Geography
7.18.6 By Therapy Area
7.18.7 By Phase
7.19 Baxter
7.19.1 Overview
7.19.2 Licensing Agreements – Baxter
7.19.3 By Value
7.19.4 By Type
7.19.5 By Therapy Area
7.20 Amgen
7.20.1 Overview
7.20.2 Licensing Agreements – Amgen
7.20.3 By Value
7.20.4 By Geography
7.20.5 By Therapy Area
7.20.6 By Phase
8 Licensing Strategies In Large Pharmaceutical Companies – Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Primary Research
8.3.4 Expert Panel Validation
8.4 Section Wise Methodology
8.4.1 Trends in In-licensing and Out-licensing Agreements
8.4.2 Product Licensing
8.4.3 Technology Licensing Deals
8.4.4 Major Licensing Deals of Big Pharma Companies – 2010
8.4.5 Licensing Strategies of Major Pharmaceutical Companies
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

Figure 1: Licensing Strategies in Large Pharmaceutical Companies , Pharmaceutical Licensing Life Cycle, 2010
Figure 2: Licensing Strategies in Large Pharmaceutical Companies, Top 20 Pharmaceuticals Licensing Deals, 2005–2010
Figure 3: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Value, 2004–2010
Figure 4: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Therapy Area, 2010
Figure 5: Licensing Strategies in Large Pharmaceutical Companies, Top 20 Pharmaceutical Companies, Number of Licensing Deals, 2010
Figure 6: Licensing Strategies in Large Pharmaceutical Companies, GSK, Number of Licensing Deals, 2005 – Q1 2011
Figure 7: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Value, 2006–2010
Figure 8: Licensing Strategies in Large Pharmaceutical Companies, GSK, Number of Licensing Deals By Value, 2005 – Q1 2011
Figure 9: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Type, 2009 – Q1 2011
Figure 10: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Geography, 2009 – Q1 2011
Figure 11: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Therapy Area, 2009–Q1 2011
Figure 12: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Phase, 2009 – Q1 2011
Figure 13: Licensing Strategies in Large Pharmaceutical Companies, J&J, Number of Licensing Deals, 2005–Q1 2011
Figure 14: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2006–2010
Figure 15: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2005 – Q1 2011
Figure 16: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Type, 2009 – Q1 2011
Figure 17: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Geography 2009 – Q1 2011
Figure 18: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 19: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Phase, 2009 – Q1 2011
Figure 20: Licensing Strategies in Large Pharmaceutical Companies, Roche, Number of Licensing Deals, 2005 – Q1 2011
Figure 21: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2006–2010
Figure 22: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2005 – Q1 2011
Figure 23: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Type, 2009–Q1 2011
Figure 24: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Geography, 2009 – Q1 2011
Figure 25: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 26: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Phase, 2009 – Q1 2011
Figure 27: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Number of Licensing Deals, 2005 – 2010
Figure 28: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Number of Licensing Deals, By Value, 2005–2010
Figure 29: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Type, 2009 – Q1 2011
Figure 30: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Geography 2009 – Q1 2011
Figure 31: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 32: Licensing Strategies in Large Pharmaceutical Companies, Abbott, Licensing Deals By Phase, 2009 – Q1 2011
Figure 33: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Number of Licensing Deals, 2005 – Q1 2011
Figure 34: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Value, 2006–2010
Figure 35: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Number of Licensing Deals, By Value, 2005 – Q1 2011
Figure 36: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Type, 2009 – Q1 2011
Figure 37: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Geography, 2009 – Q1 2011
Figure 38: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 39: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Phase, 2009 – Q1 2011
Figure 40: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Number of Licensing Deals, 2005 – Q1 2011
Figure 41: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Value, 2006–2010
Figure 42: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Number of Licensing Deals By Value, 2005 – Q1 2011
Figure 43: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Type, 2009 – Q1 2011
Figure 44: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Geography, 2009 – Q1 2011
Figure 45: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 46: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Phase, 2009 – Q1 2011
Figure 47: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Number of Licensing Deals, 2005 – Q1 2011
Figure 48: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Value, 2006 – 2010
Figure 49: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Number of Licensing Deals, By Value, 2005 – Q1 2011
Figure 50: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Type, 2009 – Q1 2011
Figure 51: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Geography, 2009 – Q1 2011
Figure 52: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 53: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Phase, 2009 – Q1 2011
Figure 54: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Number of Licensing Deals, 2005 – Q1 2011
Figure 55: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Value, 2006 – 2010
Figure 56: Licensing Strategies in Large Pharmaceutical Companies, Takedak Number of Licensing Deals, By Value, 2005 – Q1 2011
Figure 57: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Type, 2009 – Q1 2011
Figure 58: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Geography, 2009 – Q1 2011
Figure 59: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 60: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Phase, 2009 – Q1 2011
Figure 61: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Number of Licensing Deals, 2005 – Q1 2011
Figure 62: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2006–2010
Figure 63: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2005 – Q1 2011
Figure 64: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Type, 2009 – Q1 2011
Figure 65: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Geography, 2009 – Q1 2011
Figure 66: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 67: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Phase, 2009 – Q1 2011
Figure 68: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Number of Licensing Deals, 2005 – Q1 2011
Figure 69: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2006–2010
Figure 70: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2005 – Q1 2011
Figure 71: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Type, 2009 – Q1 2011
Figure 72: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Geography, 2009 – Q1 2011
Figure 73: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 74: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Phase, 2009 – Q1 2011
Figure 75: Licensing Strategies in Large Pharmaceutical Companies, Boehringer Ingelheim, Number of Licensing Deals, 2005 – Q1 2011
Figure 76: Licensing Strategies in Large Pharmaceutical Companies, Boehringer Ingelheim, Licensing Deals By Value, 2005 – 2010
Figure 77: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Number of Licensing Deals, 2005 – Q1 2011
Figure 78: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals, By Value, 2006–2010
Figure 79: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Number of Licensing Deals, By Value, 2005 – Q1 2011
Figure 80: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Type, 2009 – Q1 2011
Figure 81: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Geography, 2009 – Q1 2011
Figure 82: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 83: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Phase, 2009 – Q1 2011
Figure 84: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Number of Licensing Deals, 2005 – Q1 2011
Figure 85: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2006 – 2010
Figure 86: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2005 – Q1 2011
Figure 87: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Type, 2009 – Q1 2011
Figure 88: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Geography, 2009 – Q1 2011
Figure 89: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 90: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Phase, 2009 – Q1 2011
Figure 91: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Number of Licensing Deals, 2005 – Q1 2011
Figure 92: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Value, 2006–2010
Figure 93: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Number of Licensing Deals By Value, 2005 – 2010
Figure 94: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Type, 2009 – Q1 2011
Figure 95: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Geography, 2009 – Q1 2011
Figure 96: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 97: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Phase 2009 – Q1 2011
Figure 98: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Number of Licensing Deals, 2005 – Q1 2011
Figure 99: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Value, 2006 – 2010
Figure 100:Licensing Strategies in Large Pharmaceutical Companies, Astellas, Number of Licensing Deals By Value, 2005 – Q1 2011
Figure 101:Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Type, 2009 – Q1 2011
Figure 102:Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Geography, 2009 – Q1 2011
Figure 103:Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 104:Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Phase, 2009 – Q1 2011
Figure 105:Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Number of Licensing Deals, 2005 – Q1 2011
Figure 106:Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Number of Licensing Deals By Value, 2005 – Q1 2011
Figure 107:Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Type, 2009 – Q1 2011
Figure 108:Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Geography, 2009 – Q1 2011
Figure 109:Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals by Therapy Area, 2009 – Q1 2011
Figure 110:Licensing Strategies in Large Pharmaceutical Companies, Daiichi Sankyo, Licensing Deals By Phase, 2009 – Q1 2011
Figure 111:Licensing Strategies in Large Pharmaceutical Companies, Teva, Number of Licensing Deals, 2005 – Q1 2011
Figure 112:Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2006 – 2010
Figure 113:Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2005 – Q1 2011
Figure 114:Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Type, 2009 – Q1 2011
Figure 115:Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Geography, 2009 – Q1 2011
Figure 116:Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 117:Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Phase, 2009 – Q1 2011
Figure 118:Licensing Strategies in Large Pharmaceutical Companies, Eisai, Number of Licensing Deals, 2005 – Q1 2011
Figure 119:Licensing Strategies in Large Pharmaceutical Companies, Eisai, Number of Licensing Deals By Value, 2005 – Q1 2011
Figure 120:Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Type, 2009 – Q1 2011
Figure 121:Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Geography, 2009 – Q1 2011
Figure 122:Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 123:Licensing Strategies in Large Pharmaceutical Companies, Eisai, Licensing Deals By Phase, 2009 – Q1 2011
Figure 124:Licensing Strategies in Large Pharmaceutical Companies, Baxter, Number of Licensing Deals, 2005 – Q1 2011
Figure 125:Licensing Strategies in Large Pharmaceutical Companies, Baxter, Number of Licensing Deals By Value, 2005 – Q1 2011
Figure 126:Licensing Strategies in Large Pharmaceutical Companies, Baxter, Licensing Deals By Type, 2009 – Q1 2011
Figure 127:Licensing Strategies in Large Pharmaceutical Companies, Baxter, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 128:Licensing Strategies in Large Pharmaceutical Companies, Amgen, Number of Licensing Deals, 2005 – Q1 2011
Figure 129:Licensing Strategies in Large Pharmaceutical Companies, Amgen, Number of Licensing Deals By Value, 2005 – Q1 2011
Figure 130:Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Type, 2009 – Q1 2011
Figure 131:Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Geography, 2009 – Q1 2011
Figure 132:Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Therapy Area, 2009 – Q1 2011
Figure 133:Licensing Strategies in Large Pharmaceutical Companies, Amgen, Licensing Deals By Phase, 2009 – Q1 2011

Table 1: Licensing Strategies in Large Pharmaceutical Companies, Global, Licensing Deals By Value 2004–2010
Table 2: Licensing Strategies in Large Pharmaceutical Companies, GSK, Licensing Deals By Value, 2006–2010
Table 3: Licensing Strategies in Large Pharmaceutical Companies, J&J, Licensing Deals By Value, 2006 – 2010
Table 4: Licensing Strategies in Large Pharmaceutical Companies, Roche, Licensing Deals By Value, 2006–2010
Table 5: Licensing Strategies in Large Pharmaceutical Companies, Eli Lilly, Licensing Deals By Value, 2006–2010
Table 6: Licensing Strategies in Large Pharmaceutical Companies, Novartis, Licensing Deals By Value, 2006–2010
Table 7: Licensing Strategies in Large Pharmaceutical Companies, Sanofi, Licensing Deals By Value, 2006 – 2010
Table 8: Licensing Strategies in Large Pharmaceutical Companies, Takeda, Licensing Deals By Value, 2006 – 2010
Table 9: Licensing Strategies in Large Pharmaceutical Companies, Pfizer, Licensing Deals By Value, 2006 – 2010
Table 10: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Value, 2006 – 2010
Table 11: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Value, 2006–2010
Table 12: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2006 – 2010
Table 13: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Value, 2006 – 2010
Table 14: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Value, 2006 – 2010
Table 15: Licensing Strategies in Large Pharmaceutical Companies, Teva, Licensing Deals By Value, 2006 – 2010